Iovance Biotherapeutics Inc

16 de set. de 2026, 19:03 UTC

Iovance Biotherapeutics reported record second-quarter revenue of nearly $100 million and is preparing for multiple data updates, driving shares higher since Tuesday.

15 de set. de 2026, 23:01 UTC

Iovance Biotherapeutics is higher in after-market hours, reflecting broader market gains. No specific company news was identified to explain the movement.

14 de set. de 2026, 20:08 UTC

Iovance Biotherapeutics shares are rising amid discussions of a potential valuation at $16, reflecting levels seen in early 2021. The stock is above its 20-day moving average.

11 de set. de 2026, 19:16 UTC

Iovance Biotherapeutics is gaining amid social media discussions about an upcoming conference, with expectations for quarterly revenue exceeding $100 million.

10 de set. de 2026, 23:06 UTC

Iovance Biotherapeutics Inc shares are lower in after-market hours. The stock has seen three consecutive lower daily finishes despite recent strength over the past month.

9 de set. de 2026, 20:07 UTC

Iovance Biotherapeutics Inc shares are lower amid broader market declines, with no specific news identified to explain today's volatility.

4 de set. de 2026, 19:46 UTC

Iovance Biotherapeutics shares are higher as the company announces participation in two upcoming healthcare conferences to discuss advancements in TIL therapies.

3 de set. de 2026, 23:51 UTC

Iovance Biotherapeutics Inc shares are higher in after-market trading, maintaining a position above its 20-day moving average amid broader market gains.

2 de set. de 2026, 19:16 UTC

Iovance Biotherapeutics is up today, continuing a trend of three consecutive higher daily closes despite rising global bond yields and no specific news.

1 de set. de 2026, 23:06 UTC

Iovance Biotherapeutics Inc shares are lower in after-market hours, reflecting a slight decline since Tuesday's close amid rising oil prices and inflation concerns.

31 de ago. de 2026, 19:36 UTC

Iovance Biotherapeutics shares are lower amid increased interest rate hike expectations and uncertainties regarding its product execution and approvals.

28 de ago. de 2026, 23:11 UTC

Iovance Biotherapeutics Inc is trading higher in after-market hours, remaining near the upper end of its one-month range and above its 20-day moving average.

27 de ago. de 2026, 23:01 UTC

Iovance Biotherapeutics Inc shares are lower in after-market hours amid a broader market decline influenced by recent economic data and Fed policy expectations.

26 de ago. de 2026, 23:46 UTC

Iovance Biotherapeutics is trading higher in after-market hours, showing unusual activity and remaining above its 20-day moving average. No specific news was identified.

25 de ago. de 2026, 19:16 UTC

TD Cowen maintained a Buy rating on Iovance Biotherapeutics and raised its price target to $10, contributing to the stock's gains since Monday.

24 de ago. de 2026, 23:26 UTC

Iovance Biotherapeutics shares are higher in after-market trading, continuing an upward trajectory since Monday's close, despite recent declines over three sessions.

21 de ago. de 2026, 20:02 UTC

Iovance Biotherapeutics is lower in Friday's session, with no specific news identified. The broader market also remains down significantly since Thursday's close.

20 de ago. de 2026, 23:06 UTC

Iovance Biotherapeutics reached a 52-week high after UBS raised its target price to $7, noting strong second-quarter sales of $91 million.

19 de ago. de 2026, 23:16 UTC

Iovance Biotherapeutics shares reached a new 52-week high amid positive melanoma treatment sector sentiment and an anticipated revenue guidance increase.

18 de ago. de 2026, 23:06 UTC

Iovance Biotherapeutics shares were roughly flat in after-market hours. The broader market faced pressure from rising bond yields and increased oil prices.

17 de ago. de 2026, 19:36 UTC

Iovance Biotherapeutics reaches a new 52-week high above $7 amid positive results from the IOV-LUN-202 trial for metastatic NSCLC.

14 de ago. de 2026, 23:26 UTC

Iovance Biotherapeutics Inc. gains in after-market trading, reaching a 52-week high above $7 amid positive sentiment for IOV-LUN-202 and upcoming updates.

13 de ago. de 2026, 19:21 UTC

Iovance Biotherapeutics Inc shares are lower today, reaching a midday low after earlier gains. No specific news was identified to explain the decline.

12 de ago. de 2026, 19:16 UTC

Iovance Biotherapeutics Inc shares rise amid positive social media discussions and analyst projections of over $400 million in revenue this year.

11 de ago. de 2026, 23:46 UTC

Iovance Biotherapeutics Inc shares are lower in after-market hours amid volatility. No specific news was identified to explain the price movement.

10 de ago. de 2026, 23:56 UTC

Iovance Biotherapeutics reported second-quarter revenue of $99.3 million, a 66% increase, contributing to a rise in shares during after-market hours.

7 de ago. de 2026, 20:03 UTC

Iovance Biotherapeutics rises as Barclays and Citizens raise price targets amid positive sentiment and high trading volume.

6 de ago. de 2026, 20:03 UTC

Iovance Biotherapeutics reported record Q2 revenue of $99.3 million, exceeding estimates. The stock is higher amid strong demand and FDA Fast Track Designation for SAR-201.

5 de ago. de 2026, 23:16 UTC

Iovance Biotherapeutics shares are higher in after-market trading, reflecting broader market strength amid falling crude oil prices and strong corporate earnings.

4 de ago. de 2026, 19:51 UTC

Iovance Biotherapeutics is rising amid broader market strength from falling crude oil prices and positive economic data, despite lingering inflation concerns.